Cutaneous Lupus Erythematosus Pipeline Report Analysis by DelveInsight

October 20 19:35 2021
Cutaneous Lupus Erythematosus Pipeline Report Analysis by DelveInsight
Cutaneous Lupus Erythematosus Pipeline
DelveInsight’s Cutaneous Lupus Erythematosus pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight’s Cutaneous Lupus Erythematosus pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Some of the Key Highlights from the Cutaneous Lupus Erythematosus Pipeline Report

  • There are currently 15+ drugs in the Cutaneous Lupus Erythematosus pipeline.

  • The Cutaneous Lupus Erythematosus pipeline consists of therapies in different clinical phase stages, including SAR443122, BMS-986256, CBS004, and others.

  • Some of the companies actively working to improve the Cutaneous Lupus Erythematosus treatment landscape are Sanofi, Bristol-Myers Squibb, Centessa Pharmaceuticals, HOTH, Biogen, Centessa Pharmaceuticals, Merck, and others.

  • Denali and Sanofi announced a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors, including peripherally restricted molecules such as DNL758 and CNS-penetrant molecules such as DNL788 (SAR443820).

  • CBS004 is being developed and investigated in the preclinical stage by Centessa Pharmaceuticals.

Get a detailed analysis of the pipeline landscape @ Cutaneous Lupus Erythematosus Pipeline Analysis

Cutaneous Lupus Erythematosus: Overview

Cutaneous Lupus Erythematosus (CLE) is an autoimmune disease that can manifest as different skin disease or a systemic lupus erythematosus symptom. Cutaneous lupus erythematosus (LE) can occur as a complication of Systemic Lupus Erythematosus (SLE) or independently of SLE.

Cutaneous Lupus Erythematosus Symptoms

CLE has a broad clinical spectrum, ranging from isolated discoid plaques to widespread skin lesions. Acute cutaneous lupus erythematosus is characterized by transient erythematous patches that occur in conjunction with a flare of systemic lupus erythematosus.

Cutaneous Lupus Erythematosus Treatment

CLE treatment aims to improve skin appearance, limit scarring, and prevent new skin lesions. Sun protection is a critical preventative measure for avoiding skin lupus flares caused by UVB radiation. Pharmacological inhibition of both adaptive and innate immune responses is effective in the treatment of CLE patients. Local therapy, topical steroids, intralesional steroids, systemic therapy, antimalarials, immune modulators such as methotrexate, mycophenolate, dapsone, ciclosporin, and systemic corticosteroids are examples of specific measures.

Cutaneous Lupus Erythematosus Pipeline Analysis: Drug Profiles 

SAR443122: Sanofi

Product Description

SAR443122 (DNL758) is a small molecule RIPK1 inhibitor that does not enter the brain. RIPK1 is a tumor necrosis factor (TNF) receptor pathway signaling protein that regulates inflammation and cell death. 

Phase II

NCT04781816: Sanofi began a randomized, double-blind, placebo-controlled proof-of-concept study in April 2021 to assess the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus. The primary goal of this study is to determine the efficacy of SAR443122 in patients with cutaneous lupus erythematosus (CLE).

Cutaneous Lupus Erythematosus Pipeline Therapies and Key Companies 

  • SAR443122: Sanofi

  • BMS-986256: Bristol-Myers Squibb

  • CBS004: Centessa Pharmaceuticals

Find out the emerging therapies and companies @ Cutaneous Lupus Erythematosus Clinical Trials

Cutaneous Lupus Erythematosus Therapeutics Assessment

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

  • Targets

    • Immune System

    • Multiple Kinase

  • By Mechanism of Action

    • Protease Inhibitors

    • Immunomodulatory

Scope of the Report

Coverage: Global

Cutaneous Lupus Erythematosus Key Players: Sanofi, Bristol-Myers Squibb, Centessa Pharmaceuticals, HOTH, Biogen, Centessa Pharmaceuticals, Merck, among others

Cutaneous Lupus Erythematosus Pipeline Therapies: SAR443122, BMS-986256, CBS004, and others

Table of Contents

1.

Introduction

2.

Executive Summary

3.

Cutaneous Lupus Erythematosus: Overview

4.

Cutaneous Lupus Erythematosus Pipeline Therapeutics

5.

Cutaneous Lupus Erythematosus Late Stage Products (Pre-registration)

6.

Cutaneous Lupus Erythematosus Late Stage Products (Phase  III)

7.

Cutaneous Lupus Erythematosus Mid Stage Products (Phase  II)

8.

Cutaneous Lupus Erythematosus Early Stage Products (Phase  I)

9.

Cutaneous Lupus Erythematosus Pre-clinical and Discovery Stage Products

10.

Cutaneous Lupus Erythematosus Therapeutics Assessment

11.

Cutaneous Lupus Erythematosus Inactive Products

12.

Cutaneous Lupus Erythematosus- Unmet Needs

13.

Cutaneous Lupus Erythematosus- Market Drivers and Barriers

14.

Appendix

15.

About DelveInsight

Get in touch with our business executive for Healthcare Due Diligence Services

Key questions answered in the Cutaneous Lupus Erythematosus Pipeline Report

  • What are the treatments for Cutaneous Lupus Erythematosus?

  • How many pharmaceutical companies are working on treatments for Cutaneous Lupus Erythematosus?

  • Which of these companies’ pharmaceuticals is the most commonly used?

  • How many Each company manufactures cutaneous Lupus Erythematosus medications?

  • How many drugs are in the early, mid, or late stages of development for Cutaneous Lupus Erythematosus?

  • How many of the currently being developed therapies can be used alone or in combination with other treatments?

  • What are the essential industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices in Cutaneous Lupus Erythematosus?

Related Reports

Systemic Lupus Erythematosus Pipeline Insights

Get a comprehensive analysis of Systemic Lupus Erythematosus pipeline therapies and key companies, including GlaxoSmithKline, AstraZeneca, Biogen, Eli Lilly and Company, Xencor, Pfizer, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

view more articles

About Article Author